Maravai LifeSciences Holdings Inc. Class A Common Stock vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while First Trust NASDAQ 100 Technology Index Fund trades at $303.09 (market cap $4.40B). The key difference: First Trust NASDAQ 100 Technology Index Fund is far larger — about 4.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| MRVI | QTEC | |
|---|---|---|
Market Cap | $972.90M | $4.40B |
Volume | 4,325,710 | 160,706 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.00 | $340.28 |
52-Week Low | $2.83 | $207.03 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $324.27, down 0.59% on the day. The technical outlook is bullish based on moving averages, with key support at $321 and resistance at $335. Recent analysis highlights its equal-weighted exposure to the technology sector and better liquidity compared to peers.
The ETF offers broad tech exposure but faces sector-specific volatility risks. Upside potential hinges on technology sector performance, while downside risks include macroeconomic pressures on growth stocks. Investor sentiment remains mixed with a neutral oscillator reading.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →